After the FDA declared GLP-1 shortages resolved in early 2025 and began cracking down on compounding pharmacies, Ro and Hims & Hers shifted to partnering with Eli Lilly and Novo Nordisk's direct-to-consumer cash-pay pharmacies, LillyDirect (launched January 2024) and NovoCare (launched March 2025), that the manufacturers had built to bypass insurance and PBM channels and capture the unprecedented consumer demand around by GLP-1s, for which ~60% of patients are denied coverage by their insurers
It is important to take a complete medical history to determine the safety in individual cases
I sit between 146 and 151 lbs now
Our findings suggest that compared to insulin therapy, the higher drug acquisition, pharmacy, and outpatient costs associated with the real-world use of a GLP-1RA is offset by a reduction in healthcare-related expenses associated with emergency room visits and inpatient admissions owing to reduced risks of all-cause mortality and hospitalized hypoglycemia
"Ro not only expands access to effective GLP-1 medications, but also gives each patient regular consultations with their provider, ongoing coaching, and convenient follow-up to maintain their progress